TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19226293

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Orotracheal Intubation
Number of subjects: 134
Study: 16808741

Group type: EXPERIMENTAL
Intervention: Nicotine gum plus health education (HE) counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine gum plus motivational interviewing (MI) counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gum plus HE counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gum plus MI counseling
Number of subjects: 0
Study: 12602466

Group type: EXPERIMENTAL
Intervention: FX 60 dialyzer
Number of subjects: 8

Group type: COMPARATOR
Intervention: F 60S dialyzer
Number of subjects: 8
Study: 11469617

Group type: EXPERIMENTAL
Intervention: Vacuum-lancet device applied to the forearm
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Vacuum-lancet device
Number of subjects: 215
Study: 9519505

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 99

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 99
Study: 8229434

Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: povidone-iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no scrub)
Number of subjects: 0
Study: 3956833

Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total hysterectomy
Number of subjects: 22
Study: 31779987

Group type: EXPERIMENTAL
Intervention: Modified alternate-day fasting diet
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calorie restriction
Number of subjects: 70
Study: 26618715

Group type: EXPERIMENTAL
Intervention: 800 mg GOE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1600 mg GOE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26033058

Group type: EXPERIMENTAL
Intervention: All-polyethylene component
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metal-backed component
Number of subjects: 45
Study: 23901839

Group type: EXPERIMENTAL
Intervention: IVIG + infliximab
Number of subjects: 14

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 14
Study: 21592143

Group type: EXPERIMENTAL
Intervention: Induction procedure using traits as OS categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction procedure using traits as TS categories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no practice of traits)
Number of subjects: 0
Study: 19752363

Group type: EXPERIMENTAL
Intervention: 5g IV MgSO(4) followed by daily 4-hour infusions from postoperative day 1 until postoperative day 4
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 17562640

Group type: EXPERIMENTAL
Intervention: Attentional Focus and Symptom Management Intervention (AFSMI) during two phone sessions, at 3-4 days and 10-11 days after surgery
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 117
Study: 15083478

Group type: EXPERIMENTAL
Intervention: Methods allowing for uncertainty in intracluster correlation coefficient (ICC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods allowing for uncertainty in ICC
Number of subjects: 0
Study: 12093851

Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 5 embryo transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryopreserved embryo transfers
Number of subjects: 0
Study: 9670257

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 0
Study: 7874899

Group type: EXPERIMENTAL
Intervention: 0.50 mL normal saline injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.75 mL normal saline injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1 mL normal saline injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.25 mL normal saline injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Normal saline injections (all volumes)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control groups (nonintubated patients)
Number of subjects: 34
Study: 1699907

Group type: EXPERIMENTAL
Intervention: Raveron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 763213

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 mg of lidocaine in a 10% solution into the deltoid muscle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 mg of lidocaine in a 10% solution into the lateral vastus muscle
Number of subjects: 10
Study: 31973596

Group type: EXPERIMENTAL
Intervention: Ad-SGE-REIC
Number of subjects: 0
Study: 31503180

Group type: EXPERIMENTAL
Intervention: Paranoid ideation without psychosis (PIP)
Number of subjects: 12532

Group type: EXPERIMENTAL
Intervention: PIP symptoms (specifically 'spouse was being unfaithful')
Number of subjects: 12532

Group type: EXPERIMENTAL
Intervention: PIP in combination with major depressive disorder (MDD)
Number of subjects: 12532

Group type: EXPERIMENTAL
Intervention: PIP (specifically 'doubting spouse')
Number of subjects: 12532
Study: 29050954

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a target dose of 48-54 Gy in six fractions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Co-planar autoVMAT QA plans
Number of subjects: 20
Study: 25562685

Group type: EXPERIMENTAL
Intervention: Paliperidone monthly
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 22431145

Group type: EXPERIMENTAL
Intervention: VPT/CEM (Vital Pulp Therapy with Calcium-Enriched Mixture Cement)
Number of subjects: 407

Group type: COMPARATOR
Intervention: RCT (Root Canal Therapy)
Number of subjects: 407
Study: 21484362

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 19530584

Group type: EXPERIMENTAL
Intervention: Epidural nalbuphine 5 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Epidural nalbuphine 10 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 182
Study: 18217833

Group type: EXPERIMENTAL
Intervention: Training on visual letter recognition strings
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short amount of training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using words as stimuli
Number of subjects: 0
Study: 15302721

Group type: EXPERIMENTAL
Intervention: Nasal Proportional Assist Ventilation (PAV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 14
Study: 11559309

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine hydrochloride (2-10 mg, n = 20)
Number of subjects: 29

Group type: COMPARATOR
Intervention: pH-matched vehicle placebo (n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine hydrochloride (2-10 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: pH-matched vehicle placebo
Number of subjects: 29
Study: 9733667

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide with methylene blue (50 mg po 3 times daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous ifosfamide (one of the first two cycles)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Methylene blue administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Overall alkylating activity in urine
Number of subjects: 9
Study: 7798164

Group type: EXPERIMENTAL
Intervention: Rapid transfusion of RBC by apheresis
Number of subjects: 9
Study: 3184889

Group type: EXPERIMENTAL
Intervention: Cocaine 15 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine 40 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine (15 mg and 40 mg combined)
Number of subjects: 5
Study: 31995194

Group type: COMPARATOR
Intervention: Household ambulators
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Maximum steps per bout
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Bouts per day
Number of subjects: 252
Study: 30097164

Group type: EXPERIMENTAL
Intervention: Spironolactone (non-selective MRA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Eplerenone (selective MRA)
Number of subjects: 62
Study: 28659251

Group type: EXPERIMENTAL
Intervention: Web-based alcohol intervention
Number of subjects: 898
Study: 25163819

Group type: EXPERIMENTAL
Intervention: 17OHPC (250 mg weekly injections)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 23303045

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acute Tryptophan Depletion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Trials
Number of subjects: 24
Study: 21156272

Group type: EXPERIMENTAL
Intervention: ABT-089 (0.085-0.700 mg/kg, once daily)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: ABT-089 (0.7 mg/kg, 1.4 mg/kg, once daily)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Atomoxetine (QD)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 18651341

Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 168

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 168
Study: 16518962

Group type: COMPARATOR
Intervention: Triple therapy (zidovudine/lamivudine/efavirenz)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (abacavir/lamivudine/zidovudine/tenofovir)
Number of subjects: 114
Study: 14734394

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (1mEq/l) administration
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Specific antiarrhythmic use
Number of subjects: 874

Group type: COMPARATOR
Intervention: Historical factors (chief complaint, medical history, specific disease conditions, overall drug use)
Number of subjects: 874
Study: 10966362

Group type: EXPERIMENTAL
Intervention: First metatarsal osteotomies
Number of subjects: 114

Group type: COMPARATOR
Intervention: Hallux valgus foot
Number of subjects: 114

Group type: COMPARATOR
Intervention: Hallux valgus foot with overlap toes
Number of subjects: 114
Study: 9341056

Group type: EXPERIMENTAL
Intervention: Conventional fixed pressure CPAP (group 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Automatic CPAP at measured reference pressure (group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Automatic CPAP at estimated reference pressure (group 3)
Number of subjects: 36
Study: 7924776

Group type: EXPERIMENTAL
Intervention: Insulin infusion (720 pM.m-2.min-1) during hypoglycemia (target plasma glucose, 2.8 mM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased insulin infusion rate (1,440 pM.m-2.min-1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prolonged hypoglycemia (1 h)
Number of subjects: 24
Study: 2729537

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride 1% (Novesin)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (Xylocaine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride 1% (Novesin) without bronchoscopy (group 3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (Xylocaine) without bronchoscopy (group 3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intratracheal administration of 10 ml 0.9% NaCl (group 4)
Number of subjects: 70
Study: 921876

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 57
Study: 31895273

Group type: EXPERIMENTAL
Intervention: Senofilcon A photochromic contact lens
Number of subjects: 24
Study: 30938035

Group type: EXPERIMENTAL
Intervention: FBG target of 3.9 < FBG ≤5.6 mmol/L (Group 1)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: FBG target of 3.9 < FBG ≤6.1 mmol/L (Group 2)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: FBG target of 3.9 < FBG ≤7.0 mmol/L (Group 3)
Number of subjects: 947
Study: 29145948

Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 15415

Group type: EXPERIMENTAL
Intervention: New onset AF
Number of subjects: 15415

Group type: COMPARATOR
Intervention: Persistent or permanent AF
Number of subjects: 15415
Study: 26524106

Group type: EXPERIMENTAL
Intervention: Autologous haemopoietic stem cell transplantation (HSCT)
Number of subjects: 2000
Study: 23126492

Group type: EXPERIMENTAL
Intervention: Apical box preparation (size #60)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Apical cone preparation (apical size #25)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both interventions (apical box and apical cone)
Number of subjects: 24
Study: 21876360

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid (PUFA) supplementation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid plus fish gelatin (PUFA+FG) supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: n‐3 PUFA and n‐3 PUFA+FG supplementations
Number of subjects: 16
Study: 19561263

Group type: EXPERIMENTAL
Intervention: Immunoembolization (IE) with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at high-dose (>or=1500 microg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Chemoembolization (CE)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Regression of hepatic metastases after embolization
Number of subjects: 53

Group type: COMPARATOR
Intervention: No regression of hepatic metastases after embolization
Number of subjects: 53
Study: 16646655

Group type: EXPERIMENTAL
Intervention: Ureteroscopy training model (TMU)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Simbionix UROMentor virtual‐reality simulator (VRS)
Number of subjects: 16
Study: 14754702

Group type: EXPERIMENTAL
Intervention: ZYC101a (100 or 200 microg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Combined ZYC101a groups
Number of subjects: 161
Study: 11571979

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum (PP group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Abdominal wall retraction (AWR group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison between PP and AWR groups
Number of subjects: 34
Study: 8779400

Group type: COMPARATOR
Intervention: Randomized studies in emergency medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferred consent principle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective randomized study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feasibility of a study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent observer involvement
Number of subjects: 0
Study: 2008953

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125%
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of IT morphine and epidural bupivacaine
Number of subjects: 62
Study: 7035953

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (2 mg per kilogram of body weight per day) with prednisone in tapering doses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.15 mg per kilogram per day) with prednisone in tapering doses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cytotoxic drugs (Cyclophosphamide or Chlorambucil)
Number of subjects: 50
Study: 30839267

Group type: EXPERIMENTAL
Intervention: Intervention from Well Elderly II RCT, specific details not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omitting a small subgroup of participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of clinical meaningfulness methods
Number of subjects: 0
Study: 28380086

Group type: EXPERIMENTAL
Intervention: 0.075% CPC, 0.28% Zn and 0.05% F (CPC+Zn+F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate (CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water
Number of subjects: 60

Group type: COMPARATOR
Intervention: No rinsing
Number of subjects: 60
Study: 26099868

Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mL of 25-mg tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine + 25-mg tramadol
Number of subjects: 60
Study: 23362808

Group type: EXPERIMENTAL
Intervention: Interval-sprinting training (20 min of intermittent sprinting on a cycle ergometer: 8 s sprint, 12 s recovery) for 12 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baseline heart rate variability high-frequency power
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study: 19930728

Group type: EXPERIMENTAL
Intervention: Gastric feeding
Number of subjects: 104

Group type: COMPARATOR
Intervention: Post-pyloric feeding
Number of subjects: 104
Study: 17318453

Group type: EXPERIMENTAL
Intervention: Written method of family history assessment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Interview method of family history assessment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (information-seeking, worry, perceived risk, health literacy)
Number of subjects: 104
Study: 15330492

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract (10 g dry calyx in 0.51 L water, 9.6 mg anthocyanins)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Captopril (25 mg twice a day)
Number of subjects: 90
Study: 11583480

Group type: EXPERIMENTAL
Intervention: parecoxib sodium (1 mg, 2 mg, 5 mg, 10 mg, 20 mg, or 40 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study: 9720702

Group type: EXPERIMENTAL
Intervention: 300 mg of prednisolone in a monthly oral pulse (Group A, aged 12 to 18 years)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate as soluble tablets or syrup equivalent to prednisolone 5 mg/kg body weight every month (Group B, aged 3 to 11 years)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pulsed doses of corticosteroid (both groups)
Number of subjects: 16
Study: 8131343

Group type: EXPERIMENTAL
Intervention: alfacalcidol 0.25 microgram twice daily with calcium 500 mg twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: placebo twice daily with calcium 500 mg twice daily
Number of subjects: 66
Study: 2093414

Group type: EXPERIMENTAL
Intervention: Almitrine-raubasine
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 642493

Group type: EXPERIMENTAL
Intervention: 25 g of albumin during operation followed by 150 g/day for 5 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: No albumin
Number of subjects: 52
Study: 30910321

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 782

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 782
Study: 28382336

Group type: EXPERIMENTAL
Intervention: Fermented Maillard-reactive whey protein (F-MRP) 6 g/day for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) 6 g/day for 8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fermented Maillard-reactive whey protein (F-MRP)
Number of subjects: 80
Study: 25880486

Group type: EXPERIMENTAL
Intervention: Claims-based algorithm for identifying eligible participants
Number of subjects: 3591

Group type: COMPARATOR
Intervention: Medical record review (gold standard)
Number of subjects: 3591
Study: 23696598

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Angiographic assessment
Number of subjects: 67
Study: 21211643

Group type: EXPERIMENTAL
Intervention: Timothy grass allergy immunotherapy tablet (AIT) treatment
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 20068276

Group type: EXPERIMENTAL
Intervention: Micafungin (MCFG) 2 mg/kg/day (max 100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fosfluconazole (FF) 10 mg/kg/day (max 400 mg/day)
Number of subjects: 0
Study: 17046262

Group type: EXPERIMENTAL
Intervention: Eyes open with light touch contact
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes closed with light touch contact
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes open without light touch contact
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes closed without light touch contact
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (eyes open or closed without light touch contact)
Number of subjects: 10
Study: 14984917

Group type: EXPERIMENTAL
Intervention: Plasma brain natriuretic peptide (BNP)
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine (NE)
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA)
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone (aldo)
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Plasma endothelin
Number of subjects: 4300

Group type: COMPARATOR
Intervention: Valsartan (angiotensin receptor blocker)
Number of subjects: 4300
Study: 11444676

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) 50 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 9396556

Group type: EXPERIMENTAL
Intervention: Modified activated protein C resistance functional assay
Number of subjects: 115
Study: 8359082

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3525523

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31977076

Group type: EXPERIMENTAL
Intervention: Dronabinol (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24